share_log

Strong Week for Precigen (NASDAQ:PGEN) Shareholders Doesn't Alleviate Pain of Three-year Loss

Strong Week for Precigen (NASDAQ:PGEN) Shareholders Doesn't Alleviate Pain of Three-year Loss

Precigen(納斯達克股票代碼:PGEN)股東表現強勁的一週並不能緩解三年虧損的痛苦
Simply Wall St ·  01/26 06:49

It is doubtless a positive to see that the Precigen, Inc. (NASDAQ:PGEN) share price has gained some 41% in the last three months. But that doesn't change the fact that the returns over the last three years have been stomach churning. Indeed, the share price is down a whopping 83% in the last three years. So it sure is nice to see a bit of an improvement. The thing to think about is whether the business has really turned around. We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson.

Precigen公司(納斯達克股票代碼:PGEN)的股價在過去三個月中上漲了約41%,這無疑是一個積極因素。但這並不能改變過去三年的回報令人大跌眼鏡的事實。事實上,股價在過去三年中下跌了83%。因此,看到一點改進肯定是件好事。要考慮的是業務是否真的發生了轉機。我們真的希望任何在價格暴跌中堅持下去的人都能擁有多元化的投資組合。即使你賠了錢,你也不必輸掉教訓。

While the last three years has been tough for Precigen shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns.

儘管過去三年對Precigen的股東來說是艱難的,但上週顯示出希望的跡象。因此,讓我們來看看長期基本面,看看它們是否是負回報的驅動力。

View our latest analysis for Precigen

查看我們對 Precigen 的最新分析

Given that Precigen didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

鑑於Precigen在過去十二個月中沒有盈利,我們將專注於收入增長,以快速了解其業務發展。一般而言,沒有利潤的公司預計每年收入將增長,而且速度很快。那是因爲如果收入增長可以忽略不計,而且從來沒有盈利,就很難確信一家公司能否實現可持續發展。

Over the last three years, Precigen's revenue dropped 58% per year. That's definitely a weaker result than most pre-profit companies report. The swift share price decline at an annual compound rate of 22%, reflects this weak fundamental performance. Never forget that loss making companies with falling revenue can and do cause losses for everyday investors. It's worth remembering that investors call buying a steeply falling share price 'catching a falling knife' because it is a dangerous pass time.

在過去的三年中,Precigen的收入每年下降58%。這絕對比大多數盈利前公司報告的結果要差。股價以22%的年複合率迅速下跌,反映了這種疲軟的基本面表現。永遠不要忘記,收入下降的虧損公司可能會而且確實會給普通投資者造成損失。值得記住的是,投資者稱買入急劇下跌的股價是 “抓住一把下跌的刀子”,因爲這是一個危險的消磨時間。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以在下面看到收入和收入如何隨着時間的推移而變化(點擊圖片了解確切的值)。

earnings-and-revenue-growth
NasdaqGS:PGEN Earnings and Revenue Growth January 26th 2024
納斯達克GS:PGEN收益和收入增長 2024年1月26日

We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. If you are thinking of buying or selling Precigen stock, you should check out this free report showing analyst profit forecasts.

像我們一樣,內部人士在過去的十二個月中一直在購買股票。話雖如此,大多數人認爲收益和收入增長趨勢是更有意義的業務指南。如果您正在考慮買入或賣出Precigen股票,則應查看這份顯示分析師利潤預測的免費報告。

A Different Perspective

不同的視角

Precigen shareholders are down 12% for the year, but the market itself is up 20%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. However, the loss over the last year isn't as bad as the 13% per annum loss investors have suffered over the last half decade. We'd need to see some sustained improvements in the key metrics before we could muster much enthusiasm. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Precigen , and understanding them should be part of your investment process.

Precigen的股東今年下跌了12%,但市場本身卻上漲了20%。即使是優質股票的股價有時也會下跌,但我們希望在過於感興趣之前看到企業基本指標的改善。但是,去年的虧損並不像投資者在過去五年中遭受的每年13%的虧損那麼嚴重。我們需要看到關鍵指標的持續改善,然後才能激起極大的熱情。我發現將長期股價視爲業務績效的代表非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,投資風險的幽靈無處不在。我們已經向Precigen確定了兩個警告信號,了解它們應該是您投資過程的一部分。

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

還有很多其他公司有內部人士購買股票。你可能不想錯過這份業內人士正在收購的成長型公司的免費名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論